🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — June 30, 2026

Overnight SEC filings from June 29-30, 2026, present a mixed but actionable picture for the U.S. market. The most critical developments are centered on corporate governance and capital structure shifts, including a transformative $1.1B acquisition by Prestige Consumer Healthcare, a major JV funding deal for Eos Energy with $150M from Cerberus and Hudson Bay, and a strategic pivot to AI data centers by SK Telecom with a 15GW buildout plan. Insider activity is a dominant theme with negative signals, highlighted by a massive sell-down from the 10% owner of Hinge Health ($39M+ in two days) and compliant insider sales at CrowdStrike and Capricor Therapeutics, which dilute conviction. Period-over-period comparisons reveal severe operational distress at Harbor Diversified, where revenues collapsed 94% YoY, confirming a structural decline. On the opportunity side, Guardian Metal Resources reported a 59.6% IRR on its tungsten PEA, while AITX's FIFA World Cup deployment provides a near-term catalyst. Overall, the digest points to cautious positioning, favoring companies with strong capital allocation and growth catalysts over those with deteriorating fundamentals or heavy insider selling.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 29, 2026

The 12 filings from the S&P 500 Technology sector reveal a quiet period with no earnings reports or major corporate actions, dominated by routine director equity awards at NVIDIA and two insider sales at Datadog and Broadcom. The most significant signal is the $9.68M sale by Broadcom's Chief Legal Officer, a high-level disposal that warrants monitoring for broader insider sentiment. NVIDIA's uniform director awards (1,211 shares each) are standard compensation but underscore the company's continued alignment of board incentives with stock performance. The Datadog director sale, while under a 10b5-1 plan, adds to a pattern of insider selling in high-growth software names. No period-over-period comparisons, forward-looking guidance, or capital allocation changes were present in any filing, limiting the depth of trend analysis. The overall theme is one of routine corporate governance activity with isolated insider selling that does not yet suggest systemic sector concern but does highlight specific companies to watch.

12 high priority 12 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 29, 2026

The primary theme across these 17 filings is a wave of routine insider activity at mega-cap NASDAQ-100 constituents, dominated by director equity awards at NVIDIA and tax-withholding-related transactions at Alphabet. A single insider sale of $9.7M at Broadcom by a senior legal officer stands out as the most notable voluntary disposition. No forward-looking guidance, financial results, or period-over-period comparisons were disclosed in any filing, limiting the ability to derive fundamental performance trends. The NVIDIA director awards are standard compensation and carry no actionable signal. The Alphabet transactions are overwhelmingly neutral, connected to equity vesting and tax settlements, except for a small planned sale by the VP/CAO. Broadcom's insider sale is the only material voluntary sell, warranting mild bearish attention but is isolated. The Comcast 8-K is a placeholder with no financial content. Overall, the data suggests a period of administrative routine with no broad portfolio-level inflection point, but the Broadcom sale and the volume of Alphabet insider transactions create a nuanced picture of executive cash-out behavior that warrants monitoring.

10 high priority 7 medium 17 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — June 29, 2026

The 33 filings reveal a surge in activist and institutional activity, with several take-private proposals and significant stake accumulations. Key themes include activist investors pushing for strategic changes (JANA Partners at Alkami, Zvi Schreiber at Freightos), insider confidence through purchases (Sagtec CEO, Citizens Community Bancorp group), and passive institutional stakes crossing thresholds (Millennium at BellRing and Maravai). Period-over-period trends show deteriorating financials at PetMed Express (going concern) and insider selling at Freightos, while capital allocation remains mixed. The most critical developments are the non-binding buyout proposals for PetMed Express and Repay Holdings, and the escalated activism at Braemar Hotels & Resorts with a legal petition. Portfolio-level patterns indicate a focus on small-cap value plays and governance improvements.

22 high priority 11 medium 33 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 29, 2026

The 22 filings from S&P 500 Financials companies on June 29, 2026, reveal a sector dominated by routine director equity grants at CME Group, masking a significant negative development at MetLife. MetLife's preliminary Q2 2026 variable investment income estimate of $220M-$270M implies a steep shortfall against its annual guidance of ~$1.6B, signaling potential earnings pressure and a bearish catalyst for the insurer. In capital markets, T. Rowe Price OHA Select Private Credit Fund executed a $400M debt offering at a discount (98.9% of par), indicating ongoing demand for yield in the private credit space, while Wells Fargo Commercial Mortgage Trust completed a $475M CMBS issuance, reflecting sustained activity in commercial real estate securitization. The overwhelming volume of CME director stock awards (18 filings) represents routine compensation, not a trading signal, but the single open-market purchase by Director Shepard for ~$3.3K at $230.57 provides a minor bullish data point. No period-over-period comparisons or forward-looking guidance changes were present in the filings, limiting trend analysis, but the MetLife disclosure and the debt capital market activities offer the most actionable intelligence for the near term.

19 high priority 3 medium 22 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 29, 2026

The three filings from the S&P 500 Consumer Staples sector on June 29, 2026, reveal a sector theme of capital management and insider de-risking, with no immediate earnings or operational catalysts. Philip Morris International (PMI) is proactively deleveraging through a $1.1 billion debt prepayment, signaling financial discipline and a strengthening balance sheet, though it offers no direct revenue lift. In contrast, insider selling at both Hershey (HSY) and J.M. Smucker (SJM) creates a cautious tone, with a major trust and a top legal officer executing significant plan-based sales. The lack of any positive forward-looking guidance or upward revisions across the three filings suggests near-term uncertainty. While PMI's debt reduction is a modest positive for credit metrics, the aggregate insider selling pattern warrants a defensive posture in the staple space. No period-over-period comparisons (YoY/QoQ) were available in these specific filings, limiting trend analysis to balance sheet and insider activity.

2 high priority 1 medium 3 total filings
· daily

S&P 500 Industrials Sector SEC Filings — June 29, 2026

The S&P 500 Industrials stream is dominated by Honeywell's transformational spin-off of its Aerospace Technologies business, which completed on June 29, 2026, alongside a 1-for-2 reverse stock split. Honeywell Aerospace's FY2025 results show robust 13% revenue growth to $17.4B, but net income declined 4.6% due to a $373M litigation charge in Q4. Insider filings are predominantly benign, with no beneficial ownership reported by most directors and officers, while Caterpillar executives received modest phantom stock awards. The spin-off creates three independent entities, potentially unlocking value but introducing execution risk. No forward-looking guidance or capital allocation changes were noted in these filings.

14 high priority 14 total filings
· daily

S&P 500 Energy Sector SEC Filings — June 29, 2026

The two filings in this S&P 500 Energy digest are both 8-K announcements from Halliburton Co and Marathon Petroleum Corp, reporting the passing of director Abdulaziz F. Alkhayyal, who served on both boards. Neither filing contains financial data, operational metrics, period-over-period comparisons, forward-looking guidance, insider trading, or capital allocation details. The events are non-material (materiality score 1/10) with neutral sentiment, reflecting a governance continuity event rather than a financial catalyst. No sector-wide trends, growth rates, or margin insights can be derived from these filings. The key takeaway is the absence of actionable financial intelligence, which itself signals a quiet period for these two energy majors with no immediate operational or strategic changes expected.

2 medium 2 total filings
· daily

US Material Events SEC 8-K Filings — June 29, 2026

The June 29, 2026, regulatory filings reveal a market in flux, characterized by significant corporate restructuring and capital markets activity. The most dominant themes are transformative M&A, with major deals in the aerospace (Honeywell spin-off), space (Rocket Lab/Iridium), and biopharma (Zymeworks/Theravance) sectors, alongside a wave of dilutive financings from smaller-cap companies like Salarius Pharmaceuticals and U.S. GoldMining. A clear pattern of financial engineering is evident, with companies like MediaAlpha and Allegiant Travel actively managing debt and liabilities, while others like Acura Pharmaceuticals show deepening reliance on debt. Insider activity is limited, but notable director resignations at Volato Group and CDT Equity signal potential governance concerns. Overall, the data points to a market where large players are consolidating for scale, while smaller firms are aggressively seeking capital, creating a bifurcated landscape of opportunity and risk.

50 high priority 50 total filings
· daily

Insider Trading Pulse — June 29, 2026

Today's insider trading digest reveals a pronounced bearish tilt, with significant selling concentrated in Chinese ADRs, particularly Alibaba, where four top executives (CFO, General Counsel, Chief People Officer, and a Business Group CEO) collectively sold over $2.4 million in stock. This coordinated selling by the C-suite, despite concurrent option exercises, signals potential concerns about the company's near-term outlook or valuation. On the bullish side, insider buying is notable but highly specific: the CEO of Hammer Technology Holdings made a massive $2.68 million open-market purchase, and a director at CalciMedica invested $200k. A cluster of option exercises at Brazilian Electric Power Co (Eletrobras) by four executives, totaling over $9.9 million in value, suggests confidence in the company's restructuring progress. The TTM Technologies selling by five top executives under 10b5-1 plans is a coordinated pattern that warrants monitoring. Overall, the data suggests a bifurcated market where insiders are voting with their feet in Chinese tech while selectively deploying capital into small-cap value and turnaround situations.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — June 29, 2026

The June 29, 2026, filing batch reveals a market dominated by aggressive M&A and restructuring activity, particularly in India, alongside significant corporate actions in US SPACs and BDCs. A clear theme of 'delayed gratification' emerges, with multiple high-profile acquisitions (Zydus, Samvardhana Motherson, Lakhotia Polyesters) pushing back closing dates, signaling potential integration or financing hurdles. Conversely, the successful spin-off of Honeywell Aerospace and the Biocon subsidiary buyout represent clean, value-unlocking events. The distressed space is active, with a major insolvency reversal for Vikram Solar and ongoing CIRP proceedings for K-Lifestyle and BIL Vyapar. A notable capital flow is occurring into private credit and infrastructure, with three Golub Capital funds and PGIM Private Credit Fund launching tender offers, while Power Grid and StarlinePS make strategic bets on green energy. The unsolicited bid for Genco Shipping by Diana Shipping is a key hostile M&A situation to watch, with the offer extended after low initial acceptance.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — June 29, 2026

The June 29, 2026, filing batch for the Dow 30 is dominated by a massive corporate restructuring event: Honeywell International's completion of its three-way split, spinning off Honeywell Aerospace and executing a 1-for-2 reverse stock split. This transformative event overshadows a mixed strategic move from Verizon, which formed a 50/50 joint venture with BT Group but booked heavy one-time charges ($700M-$800M loss, plus $550M-$750M in severance and asset rationalization). Period-over-period data from the newly independent Honeywell Aerospace reveals a classic growth-versus-profitability tension: FY2025 sales surged 13% YoY, but net income declined 4.6%, with Q4 2025 profits hit by a $373M litigation settlement. Insider activity is overwhelmingly neutral, consisting of routine beneficial ownership filings and small phantom stock awards at Caterpillar, signaling no conviction trading. Capital allocation is focused on restructuring (Honeywell) and securitization (Verizon Master Trust's $1.2B ABS issuance). The key portfolio-level theme is 'unlocking value through separation,' with Honeywell's spin-off providing a potential catalyst for sector peers to consider similar moves.

15 high priority 1 medium 16 total filings
· daily

US SEC Filings Daily Market Digest — June 29, 2026

Today's 50 filings paint a picture of a market bifurcated between capital-constrained micro-caps facing existential threats and a massive, coordinated corporate action by the AllianceBernstein fund complex. The dominant theme is the Equitable-Corebridge merger, which triggers across 17 AB funds the need for new investment advisory agreements, creating a significant but non-economic administrative catalyst. In contrast, several micro-cap companies (Capstone, Picard Medical, Boxlight) are in acute distress, racing against Nasdaq delisting deadlines and relying on dilutive financing to stay afloat. However, selective opportunities exist: AstraZeneca's positive CHMP opinion for a new TNBC therapy signals a high-impact commercial catalyst, while VivoPower's selection of a global AI leader for its Norwegian data center and Decoy Therapeutics' institutional PIPE point to high-conviction bets in AI infrastructure and biotech, respectively. Overall, the digest shows a 'haves and have-nots' dynamic, with strong capital flows toward select growth stories and a punishing environment for companies with weak balance sheets.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — June 29, 2026

The two S&P 500 Healthcare filings today (ABBOTT LABORATORIES and CVS Health Corp) are both routine Form 4 filings related to tax withholding on restricted stock vesting, with no material new strategic or financial disclosures. The insider transactions are non-discretionary and carry neutral sentiment, indicating no management conviction signals. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were reported in these filings. The overall sector pulse remains stable with no immediate catalysts or red flags from this batch. Investors should focus on upcoming earnings calls and broader sector trends for actionable insights.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — June 29, 2026

This digest covers 35 filings, heavily tilted toward early-stage and micro-cap companies, with 9 SPACs, shell companies, or entities with no revenue. A clear sector-level pattern is the divergence between two defensive growth areas: insurance brokerage (QDM International, +28.5% revenue) and diabetes tech (PodcastOne, +18.4% revenue; MiniMed, +14.2% revenue), which show strong top-line momentum and improving unit economics. In contrast, energy E&P (Mexco Energy, -8.0% revenue) and security services (AmeriGuard, -11.1% revenue) are contracting. The most critical development is the dramatic turnaround in commercial metals (CMC, net earnings +108% YoY) driven by M&A, but funded with a 270% surge in interest expense, creating a potential debt risk. Across the sample, the crypto trusts (Franklin Solana, Franklin XRP, 21Shares Polkadot) are a red flag, all reporting large unrealized losses and net asset erosion despite massive capital inflows, signaling a 'value trap' in the digital asset space. Notably, cash burn is a systemic theme: 7 out of 10 companies with detailed cash flow data saw operating cash flow decline or turn negative, including AeroVironment (-$265M net loss, goodwill impairment) and Replimune (-$280M cash used, +46% YoY). Insider activity is sparse, but the few signals (like the SPAC share surrenders at Patriot Acquisition) point to dilution-avoidance maneuvers rather than confidence. The capital allocation landscape is bifurcated: Lennar repaid $736.8M in buybacks and $246.5M in dividends, signaling a mature capital return model, while growth names like Elite Pharmaceuticals (R&D -28% YoY) and AeroVironment (SG&A +179% YoY) are shifting spending from R&D to G&A, a bearish mix.

35 high priority 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — June 29, 2026

This batch of 17 proxy filings reveals a market bifurcated between capital-intensive SPACs and micro-caps facing existential liquidity crises, and a handful of stable, cash-generating businesses returning value to shareholders. The most critical theme is the wave of SPAC liquidations and reverse stock splits: Compass Digital Acquisition Corp. is on the brink of liquidation with a negative trust-to-market arbitrage, Picard Medical and Transportation & Logistics Systems are pursuing desperate reverse splits to maintain exchange listings, and M3-Brigade Acquisition V is scrambling for a 12-month extension after a failed deal. In contrast, Prestige Consumer Healthcare is executing a disciplined acquisition strategy with strong free cash flow, while Aura Biosciences is aggressively diluting shareholders to fund growth, signaling high cash burn. Insider trading activity is notably absent across the filings, suggesting a lack of conviction or a wait-and-see approach from management. The forward-looking calendar is packed with critical shareholder votes in July and August 2026, creating a high-stakes catalyst window for event-driven investors. Overall, the portfolio is dominated by governance and survival votes, with limited organic growth signals, making this a high-risk, event-driven environment.

17 high priority 17 total filings
· daily

US IPO Pipeline SEC S-1 Filings — June 29, 2026

The IPO pipeline is active with 10 filings, including 4 traditional IPOs (Forgent Power Solutions, SeeQC, Exyn Technologies, Ionic Digital), 3 S-1 resale registrations (Capstone Holding, Classover Holdings, BiomX), 2 S-4 merger registrations (Equity Residential, FS Bancorp), and 1 follow-on offering (Capstone Holding second filing). Key themes include high dilution risk from resale registrations and equity lines, mixed financial health with revenue growth but net losses, and significant insider activity absent in most filings. The most critical developments are Forgent Power Solutions' IPO with 7.1% revenue growth but a net loss swing, Ionic Digital's direct listing with no lock-ups, and FS Bancorp's accretive bank merger. Portfolio-level patterns show a tilt toward pre-revenue or loss-making companies in emerging tech (quantum, drones, biotech-defense), while traditional sectors (REITs, banks) show stability. Period-over-period trends reveal revenue growth in Forgent (7.1% YoY) and backlog expansion, but margin compression in BiomX and Capstone due to restructuring costs.

10 high priority 10 total filings
· daily

US Executive Officer Management Changes SEC — June 29, 2026

Today's 32 filings reveal a landscape of leadership realignment driven by strategic succession planning and the unlocking of value via spin-offs. The most significant trend is a wave of CFO transitions at mid-cap companies (Genesco, Freedom Holding, TransAct Technologies, Tenaya Therapeutics), signaling a focus on financial stewardship for growth. A parallel theme involves companies like Corteva and Fortune Brands Innovations using board appointments and CEO changes to drive separation strategies and operational turnarounds. While overall sentiment is predominantly neutral, the insider activity is minimal but positive, with companies like Swarmer and Pinnacle West rewarding executives with salary increases and retention awards, indicating confidence in their strategic direction. Notable risks emerge from massive potential dilution at Synergy CHC and a pattern of director departures without disagreement at several smaller firms, suggesting normal governance churn rather than distress. Opportunities exist in the new leadership at Tenaya Therapeutics and the strategic board enhancements at MiniMed Group and ITT Inc., which bring deep industry expertise to catalyze growth.

32 high priority 32 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — June 29, 2026

This digest reveals a bifurcated corporate landscape on June 29, 2026, where aggressive M&A and financing activity (e.g., Martin Marietta's $13.5B acquisition, Rocket Lab/Iridium $8B merger) coexists with acute distress signals from micro-cap companies resorting to dilutive offerings and asset sales. The most critical theme is the 'cash-for-survival' pattern: multiple distressed entities (Volato, Datavault AI, U.S. GoldMining) are executing deeply dilutive financings or selling digital assets at a loss to stave off insolvency, while healthier firms are using cheap debt to consolidate. A notable period-over-period trend is the compression of margins in capital-intensive sectors (Honeywell Aerospace Q4 net income down 25% YoY) contrasted with high-margin recurring revenue models (Iridium's 57% OEBITDA margin). Insider activity is sparse but telling, with director resignations at Volato signaling governance risk. The forward-looking catalyst calendar is dense with Q3 2026 merger closes (TOMI/Carbonium, SandRidge, Martin Marietta) and a major mid-2027 close for the Rocket Lab/Iridium deal, creating a 12-month arbitrage window. The overarching takeaway: the market is rewarding scale and recurring cash flow while punishing companies with weak balance sheets and no clear path to profitability.

45 high priority 45 total filings
· daily

US Corporate Board Director Changes SEC Filings — June 29, 2026

The 32 filings from June 29, 2026, reveal a significant wave of board and C-suite changes across US-listed companies, with a notable focus on CFO transitions and strategic board refreshment. Key themes include a high volume of CFO appointments (Genesco, TransAct Technologies, Freedom Holding Corp, Tenaya Therapeutics) and departures (Cadrenal Therapeutics, PEDEVCO), often tied to strategic pivots toward digital growth or SaaS platforms. Insider activity is limited but includes a large discretionary credit award to a Pinnacle West executive and significant salary increases at Swarmer, suggesting management confidence in those firms. Forward-looking data points to a major corporate separation at Corteva (Q4 2026) and a pending merger at Columbia Financial. Several companies are advancing gene therapy or medical device programs, while others face potential dilution or Nasdaq compliance risks, as flagged by Synergy CHC's massive equity plan and reverse split authorization. Overall, the period is characterized by active governance restructuring, with a mix of bullish signals from new leadership and bearish risks from shareholder dissent and executive departures.

32 high priority 32 total filings